IDYAIdeaya Biosciences Inc
Mkt Cap
$2.49BVolume
774,346.0052W High
$32.6752W Low
$13.45PE Ratio
-7.51IDYA Fundamentals
Price
$28.42Prev Close
$28.64Open
$28.8850D MA
$26.09Beta
1.06Avg. Volume
1.49MEPS (Annual)
-$3.36P/B
2.60Rev/Employee
$53,435.11Next-Generation Targeted Therapies Reshape Precision Oncology Landscape
Next-Generation Targeted Therapies Reshape Precision Oncology Landscape Next-Generation Targeted Therapies Reshape Precision Oncology Landscape PR Newswire VANCOUVER, BC, Oct. 15, 2025 USA News Group...
PR Newswire·9d ago
IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results...
PR Newswire·8mo ago
IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer
IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking...
PR Newswire·9mo ago
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire SOUTH SAN...
PR Newswire·9mo ago
IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events
IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events PR Newswire SOUTH SAN...
PR Newswire·9mo ago
IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance
IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan...
PR Newswire·9mo ago
IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors
IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors IDEAYA Biosciences Enters Exclusive License...
PR Newswire·10mo ago
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire SOUTH SAN...
PR Newswire·10mo ago
IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma
IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma IDEAYA...
PR Newswire·10mo ago
IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers
IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers IDEAYA Announces...
PR Newswire·10mo ago